TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| U.S. Braces for a Long Flu Season Along with the new H1N1 swine-flu virus, officials are keeping a close eye on some nasty seasonal strains. online.barrons.com |
BDSI Insider Selling Was a Blessing for Investors VFC submits: BDSI: A comment from Bluesbuff regarding the insider sales at BioDelivery Sciences (BDSI) earlier this year:Vinnie,Complete Story » seekingalpha.com |
FDA Approves Glaxo Leukemia Drug The Food and Drug Administration approved Arzerra, a leukemia treatment that will be marketed by GlaxoSmithKline for patients who have failed to respond to other therapies. online.barrons.com |
Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations (PR Newswire) Genomic Health, Inc. today announced results from five new studies on its Oncotype DX® breast cancer test, a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for patients with early-stage breast cancer. us.rd.yahoo.com |
Acorda MS Drug Gets FDA Clearance Zacks.com submits: Recently, Acorda Therapeutics Inc. (ACOR) announced that the U.S. Food and Drug Administration (FDA) has cleared its oral drug Ampyra (dalfampridine) which aims to improve walking speed in patients suffering from multiple sclerosis (MS). The company expects to launch the drug in the United States in March 2010. Ampyra is the first drug to get FDA approval for treating walking impairment in MS patients. Ampyra, previously known as Fampridine-SR, is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP), which was previously referred to as fampridine. The drug enjoys orphan drug designation from the U.S. agency, thereby providing it with seven years of market exclusivity.Complete Story » seekingalpha.com |